'iNCOVACC' is priced at Rs 800 for private markets and at Rs 325 for supplies to the government of India and state governments.
Biological E has received approval for conducting phase II/III human clinical trial of COVID-19 vaccine candidate Corbevax on children above five years and adolescents, the Department of Biotechnology (DBT) said on Friday.
'We want to make sustainability affordable.' 'We tell everyone, don't just recycle, Craste it!'
This is the world's first DNA-based vaccine against the coronavirus, and this three-dose vaccine when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from the disease as well as viral clearance
The DCGI's nod came after the subject expert committee on COVID-19 of the CSDCO last week recommended granting emergency use authorisation to Covovax for the age group of 7 to 11 years.
The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator's nod for conducting phase 2 clinical trials, the Department of Biotechnology said on Friday.
Tata Power on Saturday said it has inked a pact with IIT Delhi to work together on clean energy and other projects that can be transformed from research and development level to pilot stage. Tata Power, one of India's largest private sector integrated utilities, and the Indian Institute of Technology (IIT) Delhi have signed a Memorandum of Understanding (MoU) to collaborate in areas like smart grid technology, clean energy solutions, a company statement said. Considering the large number of experts with their excellence in different fields in IIT Delhi and Tata Power, there is an immense potential to collaborate between academia, research and domain experts from business with a high transformational impact, it added.
If things go according to plan, the vaccine would be available in the market by the end of this year.
The novel mRNA vaccine candidate, HGCO19, is supported with seed grant under the Ind-CEPI mission of the Department of Biotechnology. The mRNA vaccines do not use the conventional model to produce immune response. Instead, they carry molecular instructions to make the protein in the body through a synthetic RNA of the virus.
'We must not compromise with the standard, the quality. We don't need to be the first to launch a drug but what we need is a Made in India vaccine that the entire world can rely on'
American business tycoon and philanthropist Bill Gates, co-chair of the Bill and Melinda Gates Foundation on Friday announced an emergency relief fund of $700,000 for the flood victims of Jammu and Kashmir.
The levy has also been removed on low cost houses up to a carpet area of 60 square metres in a housing project under any housing scheme of the state government.
Sectors throw up a wishlist for the Finance Minister.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances